Latest Propel Bio Management, LLC Stock Portfolio
Propel Bio Management, LLC Performance:
2025 Q1: -4.59%YTD: -4.59%2024: -26.7%
Performance for 2025 Q1 is -4.59%, and YTD is -4.59%, and 2024 is -26.7%.
About Propel Bio Management, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Propel Bio Management, LLC reported an equity portfolio of $86.1 Millions as of 31 Mar, 2025.
The top stock holdings of Propel Bio Management, LLC are PAGP, MDGL, AKRO. The fund has invested 31.6% of it's portfolio in PLAINS GP HOLDINGS LP-CL and 11.6% of portfolio in MADRIGAL PHARMACEUTICALS.
The fund managers got completely rid off ARDELYX INC (ARDX), KYMERA THERAPEUTICS INC (KYMR) and KURA ONCOLOGY INC (KURA) stocks. They significantly reduced their stock positions in AKERO THERAPEUTICS INC (AKRO) and MADRIGAL PHARMACEUTICALS (MDGL). Propel Bio Management, LLC opened new stock positions in MILESTONE PHARMACEUTICALS (MIST) and COMPASS THERAPEUTICS INC (CMPX). The fund showed a lot of confidence in some stocks as they added substantially to MAAT PHARMA SACA, DELCATH SYSTEMS INC (DCTH) and APPLIED THERAPEUTICS INC (APLT).
The top stock holdings of Propel Bio Management, LLC are PAGP, MDGL, AKRO. The fund has invested 31.6% of it's portfolio in PLAINS GP HOLDINGS LP-CL and 11.6% of portfolio in MADRIGAL PHARMACEUTICALS.
The fund managers got completely rid off ARDELYX INC (ARDX), KYMERA THERAPEUTICS INC (KYMR) and KURA ONCOLOGY INC (KURA) stocks. They significantly reduced their stock positions in AKERO THERAPEUTICS INC (AKRO) and MADRIGAL PHARMACEUTICALS (MDGL). Propel Bio Management, LLC opened new stock positions in MILESTONE PHARMACEUTICALS (MIST) and COMPASS THERAPEUTICS INC (CMPX). The fund showed a lot of confidence in some stocks as they added substantially to MAAT PHARMA SACA, DELCATH SYSTEMS INC (DCTH) and APPLIED THERAPEUTICS INC (APLT).
Propel Bio Management, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Propel Bio Management, LLC made a return of -4.59% in the last quarter. In trailing 12 months, it's portfolio return was -47.32%.
New Buys
| Ticker | $ Bought |
|---|---|
| milestone pharmaceuticals | 1,161,390 |
| compass therapeutics inc | 433,802 |
New stocks bought by Propel Bio Management, LLC
Additions
| Ticker | % Inc. |
|---|---|
| maat pharma saca | 5,181 |
| delcath systems inc | 944 |
| applied therapeutics inc | 17.37 |
| phathom pharmaceuticals i | 14.65 |
Additions to existing portfolio by Propel Bio Management, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| akero therapeutics inc | -33.41 |
| madrigal pharmaceuticals | -30.21 |
Propel Bio Management, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| ardelyx inc | -4,821,300 |
| kura oncology inc | -1,132,300 |
| kymera therapeutics inc | -2,267,320 |
| compass pathways plc | -95,290 |
| jasper therapeutics inc | -427,600 |
Propel Bio Management, LLC got rid off the above stocks
Sector Distribution
Propel Bio Management, LLC has about 65.6% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 65.6 |
| Energy | 31.6 |
| Others | 2.8 |
Market Cap. Distribution
Propel Bio Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 49.3 |
| SMALL-CAP | 31.4 |
| MICRO-CAP | 16 |
| UNALLOCATED | 2.8 |
Stocks belong to which Index?
About 39.8% of the stocks held by Propel Bio Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 60.2 |
| RUSSELL 2000 | 39.8 |
Propel Bio Management, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Propel Bio Management, LLC
Propel Bio Management, LLC has 18 stocks in it's portfolio. About 91.7% of the portfolio is in top 10 stocks. APLT proved to be the most loss making stock for the portfolio. AKRO was the most profitable stock for Propel Bio Management, LLC last quarter.
Last Reported on: 15 May, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| PAGP | plains gp holdings lp-cl | 31.58 | 1,272,360 | 27,177,600 | unchanged | 0.00 | ||
Historical Trend of PLAINS GP HOLDINGS LP-CL Position Held By Propel Bio Management, LLCWhat % of Portfolio is PAGP?:Number of PAGP shares held:Change in No. of Shares Held: | ||||||||
| MDGL | madrigal pharmaceuticals | 11.56 | 30,032 | 9,947,500 | reduced | -30.21 | ||
| AKRO | akero therapeutics inc | 10.76 | 228,884 | 9,265,220 | reduced | -33.41 | ||
| PHAT | phathom pharmaceuticals i | 8.27 | 1,134,930 | 7,115,990 | added | 14.65 | ||
| ACHV | achieve life sciences inc | 7.61 | 2,453,090 | 6,549,760 | unchanged | 0.00 | ||
| APLT | applied therapeutics inc | 6.41 | 11,285,400 | 5,517,440 | added | 17.37 | ||
| RNA | avidity biosciences inc | 6.12 | 178,500 | 5,269,320 | unchanged | 0.00 | ||
| ABEO | abeona therapeutics inc | 3.45 | 624,022 | 2,970,340 | unchanged | 0.00 | ||
| TCRX | tscan therapeutics inc | 3.35 | 2,087,140 | 2,880,250 | unchanged | 0.00 | ||
| DCTH | delcath systems inc | 2.63 | 177,600 | 2,260,850 | added | 944 | ||
| SNDX | syndax pharmaceuticals in | 2.62 | 183,259 | 2,251,340 | unchanged | 0.00 | ||
| zevra therapeutics inc | 1.56 | 179,874 | 1,347,260 | unchanged | 0.00 | |||
| MIST | milestone pharmaceuticals | 1.35 | 1,451,560 | 1,161,390 | new | |||
| maat pharma saca | 1.21 | 166,423 | 1,038,480 | added | 5,181 | |||
| CMPX | compass therapeutics inc | 0.50 | 228,317 | 433,802 | new | |||
| ATHA | athira pharma inc | 0.49 | 1,492,790 | 425,296 | unchanged | 0.00 | ||
| EIGR | eiger biopharmaceuticals | 0.49 | 146,381 | 423,000 | unchanged | 0.00 | ||
| chinook therapeutics | 0.04 | 79,357 | 38,500 | unchanged | 0.00 | |||
| KYMR | kymera therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KURA | kura oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
